GlobeNewswire Inc | Nov 5, 2020 08:00AM EST

November 05, 2020

HORSHAM, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (STRATA), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced Dr. Dolev Rafaeli, Chief Executive Officer and Matthew Hill, Chief Financial Officer will participate in the following investor conferences:

H.C. Wainwright 6^th Annual Israel ConferenceDate: Thursday, November 12, 2020Time: 2:30 PM EasternFormat: Virtual Presentation

The presentation will not be webcast. The investor presentation will be available from the Investor Relations page of the Company's website at www.strataskin.com

Oppenheimer MedTech SummitDate: Thursday, November 12, 2020Format: 1x1 Meetings Only

A.G.P. Virtual Healthcare SymposiumDate: Thursday, November 19, 2020Format: 1x1 Meetings Only

AboutSTRATA Skin Sciences, Inc.STRATA Skin Sciences is a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions.

The Companys proprietary XTRAC excimer laser delivers a highly targeted therapeutic beam of UVB light to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, diseases, which impact over 35 million patients in the United States alone. The technology is covered by multiple patents, including exclusive rights for patents for the delivery of treatments to vitiligo patients.

STRATAs unique business model leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its in-house call center and insurance advocacy teams to increase volume for the Companys partner dermatology clinics.

The XTRAC business has used this proven DTC model to grow its domestic dermatology partner network to over 789 clinics, with a worldwide installed base of over 2,000 devices. The Company is able to offer 90% of DTC patients an introduction to physicians prescribing a reimbursable solution, using XTRAC, within a 10-mile radius of their house. The Company is a leader in dermatology in-clinic business generation for its partners.

Investor Contacts:Leigh Salvo(415) 937-5404ir@strataskin.com